Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2011

View Archived Issues

Phase I/II trials assess safety and immunogenicity of HIV vaccine F4/AS01

ATX-101 potentiates activity of chemotherapy in preclinical studies by disrupting cell cycle control

Phase I data support safety and tolerability of YH-4808 in healthy subjects

Vifor reports new hepcidin antagonists for treatment of anemia

Ambit Biosciences presents new tyrosine-protein kinase inhibitors

German researchers present novel agents for HIV

PET tracer [18F]-MK-3328 shows favorable pharmacological profile and promise in Alzheimer's disease

Kyowa Hakko Kirin begins phase III pegfilgrastim study in Japan

Novel activators of the K(Ca)2.3 channel synthesized by RaQualia researchers

Jasco Pharma and North Carolina Central University form research program

AFFiRiS' AD-02 Alzheimer's disease vaccine shows potential in phase I trial

Galapagos' GLPG-0187 enters phase Ib trial in patients with solid tumors

Oxford Vaccine Group receives grant from Action Medical Research to develop meningitis vaccine

Herceptin obtains additional approval in Japan for gastric cancer overexpressing HER2

Astellas files for Japanese approval of bixalomer for hyperphosphatemia

Janssen Pharma launches Stelara in Japan for psoriasis

Almirall launches Sativex in Spain for treatment of spasticity in MS

CTI gains rights to Chroma Therapeutics' antitumor drug tosedostat in the Americas

Collaboration established for research into beta-cell regeneration in diabetes

Phase III DEFEND-1 trial in type 1 diabetes does not meet primary endpoint

BioInvent advances phase II trial of cardiovascular drug candidate BI-204

Clinical evaluation of NVP-BKM-120 for treatment of endometrial and colorectal cancer under way

Phase I/II trial to assess safety/effectiveness of TRC-105 plus sorafenib in HCC is now recruiting

Preclinical anticancer activity supports entry of OCID-4681-S-01 in phase I trial in solid tumors

MRK-560 shows preference for PS-1-containing gamma-secretases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...